代谢综合征对慢性肾脏病患者生存预后的影响

doi:10.3969/j.issn.1006-7795.2021.04.016

首都医科大学学报 ›› 2021, Vol. 42 ›› Issue (4): 609-614.doi: 10.3969/j.issn.1006-7795.2021.04.016

代谢综合征对慢性肾脏病患者生存预后的影响

来璇¹, 张爱华^2*

1.北京大学第三医院老年内科,北京 100191;
2.首都医科大学宣武医院肾内科,北京 100053

收稿日期:2020-09-08 出版日期:2021-08-21 发布日期:2021-07-29
基金资助:
国家自然科学基金面上项目(81170706,81341022)。

Effect of metabolic syndrome on survival outcome of chronic kidney disease

Lai Xuan¹, Zhang Aihua^2*

1. Department of Geriatrics, Peking University Third Hospital, Beijing 100191, China;
2. Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Received:2020-09-08 Online:2021-08-21 Published:2021-07-29
Contact: * E-mail:zhangaihua0982@sina.com
Supported by:
National Natural Science Foundation of China(81170706,81341022).

摘要/Abstract

摘要： 目的明确代谢综合征(metabolic syndrome,MS)对慢性肾脏病(chronic kidney disease,CKD) 1~5期患者生存预后的影响。方法选取2006年1月至2008年9月于北京大学第三医院肾内科规律复诊的CKD患者作为研究对象。收集所有研究对象的一般资料、化验检查结果。随访截止时间为2016年12月31日,以全因死亡作为终点事件,采用Kaplan-Meier法及Cox回归分析筛选出影响CKD患者生存预后的独立危险因素。结果共纳入CKD分期为1~5期并完成随访的存活患者881例,其中合并MS者307例,未合并MS者574例。共有82例患者随访死亡。单因素生存分析及多因素Cox回归分析结果显示,年龄≥65岁、血清白蛋白<42 g/L、合并MS、合并心脑血管疾病是影响CKD患者生存预后的独立危险因素(P<0.05)。结论 MS是影响CKD 1~5期患者生存预后的独立危险因素,合并MS的CKD 1~5期患者死亡风险增大。

关键词: 代谢综合征, 慢性肾脏病, 生存预后, 危险因素

Abstract: Objective To investigate the the effect of metabolic syndrome (MS) on survival outcomes in patients with chronic kidney disease (CKD) stage 1-5. Methods The patients with CKD from January 2006 to September 2008 in the Department of Nephrology of Peking University Third Hospital were enrolled as the subjects of study. General data and laboratory results of all subjects were collected. The follow-up ended on December 31, 2016, with the all-cause death as the end point event. Kaplan-Meier method and Cox regression analysis were used to screen out independent risk factors for CKD survival outcome. Results A total of 881 survival patients with CKD stage 1-5 were enrolled and completed the follow-up, including 307 with MS and 574 without MS. Totally 82 patients died at the end point of follow-up. Survival analysis showed that age ≥65 years old, serum albumin＜42 g/L, MS and cardiovascular and cerebrovascular diseases were independent risk factors for survival prognosis of CKD patients(P<0.05). Conclusions Metabolic syndrome is an independent risk factor for survival outcomes of CKD 1-5 patients, and the risk of death of CKD stage 1-5 patients with MS is increased.

Key words: metabolic syndrome, chronic kidney disease, survival prognosis, risk factors

中图分类号:

来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.

Lai Xuan, Zhang Aihua. Effect of metabolic syndrome on survival outcome of chronic kidney disease[J]. Journal of Capital Medical University, 2021, 42(4): 609-614.

参考文献

[1] Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults[J]. Hypertens Res,2007,30(10):937-943.
[2] Navaneethan S D, Schold J D, Kirwan J P, et al. Metabolic syndrome, ESRD, and death in CKD[J]. Clin J Am Soc Nephrol,2013,8(6):945-952.
[3] 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中华糖尿病杂志,2004,12(3):156-161.
[4] Bakhshayeshkaram M, Roozbeh J, Heidari S T, et al. Relationships between various components of metabolic syndrome and chronic kidney disease in Shiraz, Iran[J]. Int J Endocrinol Metab,2019,17(2):e81822.
[5] Wu N, Qin Y, Chen S, et al. Association between metabolic syndrome and incident chronic kidney disease among Chinese: a nation-wide cohort study and updated meta-analysis[J]. Diabetes Metab Res Rev,2021,online ahead of print.
[6] Chen J, Kong X, Jia X, et al. Association between metabolic syndrome and chronic kidney disease in a Chinese urban population[J]. Clin Chim Acta,2017,470:103-108.
[7] Thomas G N, Schooling C M, Mcghee S M, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study[J]. Clin Endocrinol (Oxf),2007,66(5):666-671.
[8] Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population[J]. J Hypertens,2008,26(8):1602-1611.
[9] Kibria G M A, Crispen R. Prevalence and trends of chronic kidney disease and its risk factors among US adults: an analysis of NHANES 2003-18[J]. Prev Med Rep,2020,20:101193.
[10] 张丰萍,冯胜,石永兵. 代谢综合征与腹膜透析患者预后的关系[J]. 肾脏病与透析肾移植杂志,2012,21(5):435-438.
[11] Vogt B P, Souza P L, Minicucci M F, et al. Metabolic syndrome criteria as predictors of insulin resistance, inflammation and mortality in chronic hemodialysis patients[J]. Metab Syndr Relat Disord,2014,12(8):443-449.
[12] Rhee C M, Ahmadi S F, Kalantar-Zadeh K. The dual roles of obesity in chronic kidney disease: a review of the current literature[J]. Curr Opin Nephrol Hypertens,2016,25(3):208-216.
[13] Do Sameiro M-Faria, Ribeiro S, Costa E, et al. Risk factors for mortality in hemodialysis patients: two-year follow-up study[J]. Dis Markers,2013,35(6):791-798.
[14] Chiu H, Wu P Y, Huang J C, et al. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5[J]. Sci Rep,2020,10(1):12749.
[15] Silbernagel G, Genser B, Drechsler C, et al. HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients[J].J Am Soc Nephrol,2015,26(2):484-492.
[16] Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function[J] J Am Soc Nephrol,2011,22(9):1631-1641.
[17] Marques G L, Hayashi S, Bjällmark A, et al. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5[J]. Sci Rep,2021,11(1):2473.
[18] Jagadeswaran D, Indhumathi E, Hemamalini A J, et al. Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients[J] Clin Nutr,2019,38(1):341-347.

代谢综合征对慢性肾脏病患者生存预后的影响

Effect of metabolic syndrome on survival outcome of chronic kidney disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	冯颖, 时克, 王宪波. 肝硬化合并肠系膜上静脉栓塞患者2年预后预测模型的构建与验证[J]. 首都医科大学学报, 2023, 44(1): 107-114.
[2]	苏志燕, 刘薇, 史婷婷. 老年2型糖尿病患者血尿酸浓度与代谢综合征的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 137-142.
[3]	王剑磊, 朱天, 韩玉, 王月, 汶春苗, 位嘉. 男性尖锐湿疣患者人乳头瘤病毒基因型分布特点及复发危险因素[J]. 首都医科大学学报, 2023, 44(1): 148-153.
[4]	谷丰, 姜维, 刘宇航, 翟惠虹. 内镜黏膜下剥离术治疗结直肠肿瘤不完整切除和手术时间延长的风险因素[J]. 首都医科大学学报, 2022, 43(6): 959-965.
[5]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[6]	陈晓媚, 马圆媛, 聂静, 朱风新. 急性肾损伤向慢性肾脏病转化中肾小管上皮细胞损伤修复机制的研究进展[J]. 首都医科大学学报, 2022, 43(5): 720-727.
[7]	张志丽, 郭彩霞. 头颈部恶性肿瘤术后急性肺栓塞临床特点及危险因素分析[J]. 首都医科大学学报, 2022, 43(5): 787-791.
[8]	张静涛, 王欣然, 韩斌如, 强莹, 刘雪琪, 张毅. 老年肺癌患者胸腔镜肺切除术后并发心律失常的临床特征及危险因素分析[J]. 首都医科大学学报, 2022, 43(4): 564-569.
[9]	任春琦, 孔羽, 伏圣高, 朱正炎, 杜昕. 中青年钙化性主动脉瓣疾病的特征及危险因素分析[J]. 首都医科大学学报, 2022, 43(2): 187-191.
[10]	王荣欣, 王晶, 胡水清. 伴有食管外症状的反流性食管炎患者的危险因素分析[J]. 首都医科大学学报, 2022, 43(1): 132-137.
[11]	齐志丽, 林瑾, 董磊, 刘景峰, 段美丽. 重症监护病房血流感染危险因素的Meta分析[J]. 首都医科大学学报, 2021, 42(6): 923-930.
[12]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[13]	邢洁, 任竣瑶, 张倩, 孙秀静, 岳冰, 张一骏, 李荣雪, 朱圣韬, 李鹏, 张澍田. 结直肠腺瘤性息肉发生的危险因素分析[J]. 首都医科大学学报, 2021, 42(4): 601-608.
[14]	张爽, 马向科, 刘思维. 高血压脑出血合并肺部感染危险因素分析及防治[J]. 首都医科大学学报, 2021, 42(4): 660-663.
[15]	孙熙木, 王华光, 赵昕, 吕少诚, 贺强, 刘丽宏. 肝移植患者术后巨细胞病毒感染的危险因素分析[J]. 首都医科大学学报, 2021, 42(4): 664-671.